Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Oct 28, 2006; 12(40): 6522-6526
Published online Oct 28, 2006. doi: 10.3748/wjg.v12.i40.6522
Published online Oct 28, 2006. doi: 10.3748/wjg.v12.i40.6522
Table 3 Adverse reactions
| Grade (%) | ||||
| 1 | 2 | 3 | 4 | |
| Hematologic | ||||
| Leukopenia | 1 (3) | 14 (45) | 8 (26) | 3 (10) |
| Neutropenia | 1 (3) | 2 (6) | 13 (42) | 11 (35) |
| Thrombocytopenia | 8 (25) | 1 (3) | 1 (3) | 1 (3) |
| Anemia | 5 (16) | 13 (42) | 7 (23) | 2 (6) |
| Nonhematologic | ||||
| Fatigue | 3 (10) | 0 | 0 | 0 |
| Nausea | 12 (39) | 8 (26) | 3 (10) | 0 |
| Diarrhea | 9 (29) | 4 (13) | 1 (3) | 0 |
| Abdo pain | 2 (6) | 2 (6) | 1 (3) | 0 |
| Alopecia | 11 (35) | 10 (30) | 1 (3) | 0 |
| AST | 1 (3) | 0 | 0 | 0 |
| T. bilirubin | 1 (3) | 0 | 0 | 0 |
| Cr | 8 (26) | 0 | 0 | 0 |
- Citation: Imamura H, Ikeda M, Furukawa H, Tsujinaka T, Fujitani K, Kobayashi K, Narahara H, Kato M, Imamoto H, Takabayashi A, Tsukuma H. Phase II study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer. World J Gastroenterol 2006; 12(40): 6522-6526
- URL: https://www.wjgnet.com/1007-9327/full/v12/i40/6522.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i40.6522